A Phase 3 Study of Rotigotine in Combination with Rivastigmine in Mild to Moderate Alzheimer's Disease

This Phase 3 study is testing whether adding the drug rotigotine (a dopamine-boosting patch also used for Parkinson's disease) to an existing Alzheimer's medication called rivastigmine can improve thinking and memory in people with mild-to-moderate Alzheimer's disease. **You may be eligible if...** - You are between 50 and 85 years old - You have been diagnosed with Alzheimer's disease - You have been taking the rivastigmine skin patch at the correct dose for at least 3 months - Your memory and thinking scores fall in the mild-to-moderate range (MMSE score between 18 and 26) - A caregiver who lives with you or sees you regularly is available to help with the study - You have brain imaging or fluid test results supporting the Alzheimer's diagnosis **You may NOT be eligible if...** - You have severe Alzheimer's disease or another type of dementia - You have significant depression - You have less than 5 years of formal education - Your general health is not adequate for participation Talk to your doctor to see if this trial is right for you.